Community-based Neuroendocrine Tumor (NET) Research Study

Inclusion Criteria: * Histologically confirmed locally advanced or metastatic, well-differentiated neuroendocrine tumor (NET) of the small bowel, stomach, colon/rectum, or pancreas (low or intermediate grade; i.e. G1 or G2) * Treatment with lanreotide depot (Somatostatin Analogue-naïve patients and patients with prior treatment with octreotide long-acting repeatable (LAR) are permitted) * Radiographically measurable disease * Has signed the most recent written Patient Informed Consent Form Exclusion Criteria: * Known hypersensitivity to lanreotide * Poorly differentiated or high grade carcinoma, or patients with neuroendocrine tumors not of lung or thymic origin * Patients who have previously initiated treatment with lanreotide depot prior to the start of the study cannot have progressed between lanreotide initiation and study entry * Significant history of uncontrolled cardiac disease (ie, myocardial infarction within 6 months prior to enrollment or has congestive heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities)